Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Provention Bio Inc (PRVB)

Provention Bio Inc (PRVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,367,629
  • Shares Outstanding, K 94,781
  • Annual Sales, $ 12,900 K
  • Annual Income, $ -113,570 K
  • 60-Month Beta 2.47
  • Price/Sales 178.10
  • Price/Cash Flow N/A
  • Price/Book 17.88
Trade PRVB with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.53
  • Most Recent Earnings $-0.38 on 03/29/23
  • Next Earnings Date 05/04/23
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/23
See More
  • Average Estimate -0.96
  • Number of Estimates 2
  • High Estimate -0.39
  • Low Estimate -1.54
  • Prior Year -0.35
  • Growth Rate Est. (year over year) -174.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.82 +4.87%
on 03/27/23
25.00 -0.08%
on 04/26/23
+1.09 (+4.56%)
since 03/24/23
3-Month
6.59 +279.06%
on 03/10/23
25.00 -0.08%
on 04/26/23
+16.27 (+186.80%)
since 01/26/23
52-Week
3.18 +684.30%
on 07/05/22
25.00 -0.08%
on 04/26/23
+19.95 (+396.62%)
since 04/26/22

Most Recent Stories

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMED, PRVB, INFI

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

GMED : 71.07 (+0.45%)
PRVB : 24.98 (+3.10%)
INFI : 0.0080 (-50.00%)
PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Provention Bio, Inc. (NasdaqGS: PRVB) to Sanofi...

PRVB : 24.98 (+3.10%)
SNY : 51.33 (+0.23%)
Is Sanofi Stock a Buy Now?

The pharma giant has outperformed the broader market over the past 12 months.

PRVB : 24.98 (+3.10%)
SNY : 51.33 (+0.23%)
Why Provention Bio Stock Skyrocketed 256% This Week

Provention Bio is currently a partner of Sanofi. It should soon become a part of the big French drugmaker.

PRVB : 24.98 (+3.10%)
SNY : 51.33 (+0.23%)
Why Shares of MacroGenics Climbed Thursday

The cancer-focused biotech delivered a strong earnings report.

INCY : 63.66 (+2.20%)
PRVB : 24.98 (+3.10%)
MGNX : 4.70 (+1.08%)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Provention Bio, Inc. - PRVB

/PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national...

PRVB : 24.98 (+3.10%)
PROVENTION BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Provention Bio, Inc. - PRVB

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Provention Bio, Inc. (NasdaqGS: PRVB) to Sanofi...

PRVB : 24.98 (+3.10%)
SNY : 51.33 (+0.23%)
Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners

On a volatile market day, companies are still looking for smart combinations.

COMP : 4.11 (+3.53%)
$NASX : 18,398.45 (+0.63%)
$DOWI : 40,000.90 (+0.62%)
$SPX : 5,615.35 (+0.55%)
PRVB : 24.98 (+3.10%)
SGEN : 228.74 (-0.07%)
SNY : 51.33 (+0.23%)
PFE : 28.92 (+0.91%)
KeyCorp, Philips 66 fall; Seagen, Insulet rise

Stocks that traded heavily or had substantial price changes Monday: KeyCorp, Philips 66 fall; Seagen, Insulet rise

ILMN : 116.09 (-1.62%)
PODD : 201.98 (-0.81%)
PFE : 28.92 (+0.91%)
SBNY : 2.2500 (+9.76%)
KEY : 15.21 (+0.53%)
SIVB : 106.04 (-60.41%)
XM : 18.14 (unch)
PRVB : 24.98 (+3.10%)
Sanofi (NASDAQ: SNY) Set to Acquire Provention Bio (NASDAQ: PRVB) for $2.9 Billion

Provention Bio, Inc. (NASDAQ: PRVB) is engaged as a commercial-stage biopharmaceutical company, which is focused on the research, development and

SNY : 51.33 (+0.23%)
PRVB : 24.98 (+3.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Provention Bio, Inc. is a biopharmaceutical company. It focuses on development of novel therapeutics and solutions to intercept and prevent immune-mediated disease. The company's product pipeline consists of PRV-031, PRV-6527, PRV-300, PRV-3279 and PRV-101 which are in clinical stage. Provention Bio,...

See More

Key Turning Points

3rd Resistance Point 25.01
2nd Resistance Point 25.01
1st Resistance Point 24.99
Last Price 24.98
1st Support Level 24.97
2nd Support Level 24.97
3rd Support Level 24.95

See More

52-Week High 25.00
Last Price 24.98
Fibonacci 61.8% 16.67
Fibonacci 50% 14.09
Fibonacci 38.2% 11.52
52-Week Low 3.18

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar